Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
LPTX 
Leap Therapeutics Inc (LPTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: LPTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -73.82% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 12.97M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 4003405 | Beta 0.21 | 52 Weeks Range 0.22 - 4.79 | Updated Date 04/4/2025 |
52 Weeks Range 0.22 - 4.79 | Updated Date 04/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.81 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-17 | When Before Market | Estimate -0.36 | Actual -0.37 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -71.81% | Return on Equity (TTM) -142.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -34011610 | Price to Sales(TTM) 160.1 |
Enterprise Value -34011610 | Price to Sales(TTM) 160.1 | ||
Enterprise Value to Revenue 1.9 | Enterprise Value to EBITDA 0.47 | Shares Outstanding 41257600 | Shares Floating 31782794 |
Shares Outstanding 41257600 | Shares Floating 31782794 | ||
Percent Insiders 3.16 | Percent Institutions 48.57 |
Analyst Ratings
Rating 4.33 | Target Price 9.83 | Buy 2 | Strong Buy 1 |
Buy 2 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Leap Therapeutics Inc
Company Overview
History and Background
Leap Therapeutics, Inc. is a biopharmaceutical company focused on developing targeted immuno-oncology therapeutics. Founded in 2011, the company has focused on developing novel antibody therapies targeting cancer.
Core Business Areas
- DKN-01: DKN-01 is Leap Therapeutics' lead clinical candidate, a humanized IgG1 monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. It is being developed for various solid tumors in combination with other therapies.
Leadership and Structure
Leap Therapeutics is led by a management team with experience in drug development and oncology. The company has a board of directors overseeing its operations and strategy.
Top Products and Market Share
Key Offerings
- DKN-01: DKN-01 is Leap's primary focus, in Phase 2 and Phase 3 clinical trials across various cancers, targeting DKK1. It's market share data is yet to be determined as the product is still in clinical trials, however DKN-01 is in competition with other cancer therapy such as: small molecule tyrosine kinase inhibitors, immune checkpoint inhibitors, and chemotherapy agents.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and innovative, with companies focusing on developing new therapies for unmet medical needs. Immuno-oncology is a growing area, with therapies aimed at harnessing the body's immune system to fight cancer.
Positioning
Leap Therapeutics is positioned as a developer of novel immuno-oncology therapies, focusing on DKN-01. Its competitive advantage lies in its targeting of DKK1, a novel target in cancer.
Total Addressable Market (TAM)
The TAM for cancer therapies is significant, estimated in the hundreds of billions of dollars. Leap Therapeutics is positioned to capture a portion of this TAM with its DKN-01 program.
Upturn SWOT Analysis
Strengths
- Novel DKK1 target
- DKN-01 clinical development progress
- Experienced management team
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on DKN-01 success
- Clinical trial risks and regulatory hurdles
Opportunities
- Potential for DKN-01 to address unmet medical needs in various cancers
- Partnerships and collaborations with larger pharmaceutical companies
- Expansion of pipeline through additional drug development programs
Threats
- Competition from other immuno-oncology therapies
- Clinical trial failures
- Regulatory setbacks
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- MRK
- BMY
- PFE
Competitive Landscape
Leap Therapeutics faces competition from established pharmaceutical companies with broader pipelines and greater resources. Leap's advantages are tied to the uniqueness of their DKK1 inhibitors.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been tied to clinical trial advancements and partnership agreements.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization of DKN-01.
Recent Initiatives: Recent initiatives include advancing DKN-01 through clinical trials, securing partnerships, and raising capital.
Summary
Leap Therapeutics is a biopharmaceutical firm with a focus on immuno-oncology. It's largely dependent on the development and successful commercialization of DKN-01. Its position as a smaller company makes it more vulnerable to setbacks in development. However, should the clinical trials of DKN-01 prove successful, the company is set up for potential exponential growth.
Similar Companies
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
MRK
Merck & Company Inc
MRK
Merck & Company Inc
PFE
Pfizer Inc
PFE
Pfizer Inc
Sources and Disclaimers
Data Sources:
- Leap Therapeutics Investor Relations
- SEC Filings
- Company Press Releases
- Yahoo Finance
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is based on available information and may not be precise. Clinical trial outcomes are uncertain, and regulatory approvals are not guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Leap Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2017-01-25 | CFO, General Counsel, Treasurer & Secretary, President, CEO & Director Mr. Douglas E. Onsi J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 52 | Website https://www.leaptx.com |
Full time employees 52 | Website https://www.leaptx.com | ||
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.